US Stock Shift: Freenome Surges on October 20; New Lung Cancer Screening Product Plus Dual Cancer Screening with Single Blood Draw

Freenome October 20 Rally Interpretation

Keywords: New lung cancer screening product, dual cancer screening with a single blood draw

1. On October 20, 2026, Freenome announced the launch of the SimpleScreen Lung blood-based lung cancer screening test. Independent cohort data showed a sensitivity of 85%, specificity of 50%, and a negative predictive value of 99.8% in the target population.

2. On October 20, 2026, the company introduced a solution for screening both lung and colorectal cancer with a single blood draw: SimpleScreen Lung is intended for people aged 50 to 80 with a smoking history of at least 20 pack-years who have not yet participated in guideline-recommended screening; eligible individuals can also choose to use the FDA-approved SimpleScreen CRC at the same time.

(Disclaimer: This content is generated by AI technology, summarizing publicly available information. It is for reference only and does not constitute investment advice.)